ClinicalTrials.gg
CompletedNCT00419250Updated Nov 8, 2019

A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

A Phase 1 interventional study of lenalidomide and lenalidomide in Chronic Lymphocytic Leukemia and Leukemia, B-Cell, Chronic, sponsored by Celgene. Completed at 35 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-08.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 5 under way, none of them phase 3. Lenalidomide · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
14th of 77
52 · median 29
Started
2006
the only one that year
Phase 1
19 of 78
none open now
Registered
4th of 78
by date
Lead sponsor
4 of 78
Celgene

Among the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 14th largest by enrollment of the 77 interventional ones that give a count, is the only one that started in 2006, is one of 19 in phase 1, and was the 4th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety of lenalidomide and to define the maximum tolerated escalation dose level (MTEDL) when administered by a stepwise dose-escalation schedule in subjects with relapsed or refractory B-cell CLL.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Leukemia, B-Cell, Chronic

Keywords

  • relapsed
  • refractory
  • fludarabine
  • Revlimid
  • lenalidomide
  • CLL
  • B-cell CLL
  • CC-5013
  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of B-cell CLL that has after or is refractory to at least one prior regimen. The prior regimen(s) must have included an alkylating agent and fludarabine (used in combination or separately)
  • \< or = 2
  • Willing to agree to follow the pregnancy precautions.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing women
  • Systemic treatment for B-cell CLL within 28 days of study start
  • Central nervous system involvement
  • History of renal failure requiring dialysis
  • Prior treatment with lenalidomide
  • Alemtuzumab therapy within 56 days of initiating lenalidomide treatment
  • ANC \< 1000 / ul
  • count \< 50,000 / ul
  • Calculated \< 60 mL/min (Cockroft-Gault method)
  • or ALT > 3.0 x
  • Serum total > 2.0 mg/dl
  • Neuropathy > or = Grade 2
  • Uncontrolled hemolytic anemia or thrombocytopenia
  • Richter's transformation (active)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    dose-escalation to 5 mg lenalidomide (len)

    escalate up to 5 mg once daily / 28-day cycle

    Drug: lenalidomide

  • Experimental
    dose-escalation to 10 mg lenalidomide (len)

    escalate up to 10 mg once daily / 28-day cycle

    Drug: lenalidomide

  • Experimental
    dose-escalation to 15 mg lenalidomide (len)

    escalate up to 15 mg once daily / 28-day cycle

    Drug: lenalidomide

  • Experimental
    dose-escalation to 20 mg lenalidomide (len)

    escalate up to 20 mg once daily / 28-day cycle

    Drug: lenalidomide

  • Experimental
    dose-escalation to 25 mg lenalidomide (len)

    escalate up to 25 mg once daily / 28-day cycle

    Drug: lenalidomide

Interventions

06

What researchers measure

Primary outcomes

  1. Safety

    Time frame: February 2010

Secondary outcomes

  1. Response

    Time frame: February 2010

  2. Duration of response

    Time frame: February 2010

  3. Time to response

    Time frame: February 2010

  4. Progression free survival

    Time frame: February 2010

  5. Overall survival

    Time frame: February 2010

  6. Absolute lymphocyte count

    Time frame: February 2010

  7. Evaluation of minimal residual disease (MRD) by flow cytometry

    Time frame: February 2010

07

Study locations

35 sites
  • Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • Alta Bates Summit Comprehensive Cancer Center
    Berkeley, California 94704, United States
  • Desert Hematology Oncology Medical Group, Inc.
    Rancho Mirage, California 92270, United States
  • Baptist Cancer Institute
    Jacksonville, Florida 32207, United States
  • Cancer & Blood Disease Center
    Lecanto, Florida 34461, United States
  • Northwest Georgia Oncology Centers, PC., Wellstar Health System
    Marietta, Georgia 30060, United States
  • Mountain States Tumor Institute
    Boise, Idaho 83712, United States
  • Robert H. Lurie Comprehensive Cancer Center
    Chicago, Illinois 60611, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637-1470, United States
  • Indiana University Medical center
    Indianapolis, Indiana 46202-5149, United States
  • LSU Health Sciences Center, Feist-Weiller Cancer Center
    Shreveport, Louisiana 71130, United States
  • Karmanos Cancer Institute/Wayne State University School of Medicine
    Detroit, Michigan 48201, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Weill Medical College of Cornell University, Division of Hematology & Oncology
    New York, New York 10021, United States
  • SUNY Upstate Medical Center
    Syracuse, New York 13210, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Abington Hematology Oncology Assoc., Inc.
    Willow Grove, Pennsylvania 19090, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Cancer Care Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • Juravinski Cancer Centre
    Hamilton, Ontario L8V 5C2, Canada
  • London Helath Science Centre
    London, Ontario N6C 6B5, Canada
  • Saskatoon Cancer Centre
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Charité, Campus Benjamin Franklin, Medizinische Klinik III
    Hindenburgdamm 30, Berlin 12203, Germany
  • Uniklinik Köln, Klinik I für Innere Medizin, Klinisches Studienzentrum Hämatologie
    Bettenhaus Ebene 04, Raum 001/048, Kerpener Str. 62, Koln 50924, Germany
  • University of Schleswig Holstein, Director Medizinische Klinik II
    Campus Kiel, Chemnitzstrasse 33, Kiel, 24116, Germany
  • University of Ulm, Abteilung Innere Medizin III, Robert-Koch-Strasse 8
    Ulm, 89081, Germany
  • Clinica Ematologica- A.O.U. San Martino, Clinica Ematologica Dipartimento di Medicina Interna
    Genova, 16132, Italy
  • Hospital Clinic Provincial de Barcelona, Servicio de Hematología, Institute of Haematology and Oncology
    Villaroel, 170, Barcelona, 8036, Spain
  • Karolinska Universitetssjukhuset, Hematologiskt Centrum, Karolinska Universitetssjukhuset,
    Stockholm, 141 86, Sweden
  • St James's Institute of Oncology, Dept. of Haematology, Level 3, Bexley Wing, Beckett Street
    Leeds, LS9 7TF, United Kingdom
  • Bart's and the London NHS Trust, St. Bartholomew's Hospital, 7th Floor Gloucester House, Cancer Services
    London, EC1A 7BE, United Kingdom
  • Christie Hospital NHS Foundation Trust, Haematology and Transplant Unit,
    Manchester, M20 4BX, United Kingdom
08

References and documents

Publications

  • Wendtner CM, Hillmen P, Mahadevan D, Buhler A, Uharek L, Coutre S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Mar;53(3):417-23. doi: 10.3109/10428194.2011.618232. Epub 2011 Nov 15. PubMed 21879809 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2006 to primary completion in Feb 2010, 38 months.

Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 38 months is below that.

Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2007
First posted
Jan 8, 2007
StartActual
Dec 1, 2006
Primary completionActual
Feb 1, 2010
CompletionActual
Jun 1, 2010
Last update
Nov 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00419250
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jan 8, 2007
Start date
Dec 1, 2006
Primary completion
Feb 1, 2010
Completion
Jun 1, 2010
Last update
Nov 8, 2019

Study contacts

Elayne Lombardy, MD
study director · Celgene Corporation
Asher Chanan-Khan, MD
principal investigator · Roswell Park Cancer Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion